Literature DB >> 16684090

Laparoscopic vs open subtotal colectomy for benign and malignant disease.

H S Tilney1, R E Lovegrove, S Purkayastha, A G Heriot, A W Darzi, P P Tekkis.   

Abstract

AIM: The present meta-analysis aims to compare short-term and long-term outcomes in patients undergoing laparoscopic or open subtotal colectomy for benign and malignant disease.
METHODS: A literature search of Medline, Ovid, Embase and Cochrane databases was performed to identify studies published between 1992 and 2005, comparing laparoscopic (LSC) and open (OSC) subtotal colectomy. A random effect meta-analytical technique was used and sensitivity analysis performed on studies published since the beginning of 2000, higher quality papers, those reporting on more than 40 patients, and those studies reporting on adult cases or acute colitis.
RESULTS: A total of eight studies satisfied the criteria for inclusion. These included outcomes on 336 patients, 143 (42.6%) of whom had undergone laparoscopic resection, with an overall conversion rate to open surgery of 5% (range 0-11.8%). Operative time was significantly longer in the laparoscopic group by 86.2 min (P < 0.001) and throughout subgroup analysis, although it was only in patients with acute colitis that this finding was without significant heterogeneity. Operative blood loss was less in the laparoscopic group by 57.5 millilitres in high quality and studies published since 2000, and 65.3 millilitres in those reporting on more than 40 patients. There was no significant difference in early or long-term complications between the groups. A statistically significant reduction in length of postoperative stay was observed in the laparoscopic groups by 2.9 days (P < 0.001).
CONCLUSION: Laparoscopic subtotal colectomy was associated with longer operating times but a reduced length of stay compared to open surgery. Although short-term outcomes were equivalent in both groups, the suggested benefits in terms of reduced long-term obstructive complications were not supported by this meta-analysis.

Entities:  

Mesh:

Year:  2006        PMID: 16684090     DOI: 10.1111/j.1463-1318.2006.00959.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  6 in total

1.  Laparoscopic total colectomy: Does the indication influence the outcome?

Authors:  Eddy Cotte; Faheez Mohamed; Stéphane Nancey; Yves François; Olivier Glehen; Bernard Flourié; Jean-Christophe Saurin; Gilles Poncet
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Institution learning curve of laparoscopic colectomy--a multi-dimensional analysis.

Authors:  Jimmy C M Li; Anthony W I Lo; Sophie S F Hon; Simon S M Ng; Janet F Y Lee; Ka Lau Leung
Journal:  Int J Colorectal Dis       Date:  2011-11-30       Impact factor: 2.571

3.  Learning curves for laparoscopic sigmoidectomy used to manage curable sigmoid colon cancer: single-institute, three-surgeon experience.

Authors:  Dong Hyun Choi; Woon Kyung Jeong; Sang-Woo Lim; Tae Sung Chung; Jung-In Park; Seok-Byung Lim; Hyo Seong Choi; Byung-Ho Nam; Hee Jin Chang; Seung-Yong Jeong
Journal:  Surg Endosc       Date:  2008-02-13       Impact factor: 4.584

4.  The learning curve for laparoscopic colectomy: experience of a surgical fellow in an university colorectal unit.

Authors:  Jimmy C M Li; Sophie S F Hon; Simon S M Ng; Janet F Y Lee; Raymond Y C Yiu; Ka Lau Leung
Journal:  Surg Endosc       Date:  2009-05-19       Impact factor: 4.584

5.  Short-term outcomes of laparoscopic total mesorectal excision following neoadjuvant chemoradiotherapy.

Authors:  P Denoya; H Wang; D Sands; J Nogueras; E Weiss; Steven D Wexner
Journal:  Surg Endosc       Date:  2009-10-23       Impact factor: 4.584

6.  Evidence based medicine and surgical approaches for colon cancer: evidences, benefits and limitations of the laparoscopic vs open resection.

Authors:  Laura Lorenzon; Marco La Torre; Vincenzo Ziparo; Francesco Montebelli; Paolo Mercantini; Genoveffa Balducci; Mario Ferri
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.